In breast cancer, loss of Tp53 upregulates the secretion of WNT ligands, which stimulate macrophages to produce IL-1β, mediate neutrophilic inflammation, and potentiate metastatic progression (Wellenstein et al., 2019). Here, TP53 is linked to breast carcinoma.